There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387
July 1, 2025
NanoViricides’ decision to prioritize mpox as the first indication for its broad-spectrum antiviral candidate NV-387 marks a critical step in epidemic preparedness. With Phase II clinical trials soon to begin in the Democratic Republic of Congo, this novel oral gummy formulation could address urgent treatment gaps, especially in low-resource settings. As other antivirals like tecovirimat fail to show efficacy, NV-387’s promising animal data and host-mimetic nanomedicine approach offer hope. If proven effective, NV-387 could not only fill a void in global mpox treatment but also earn a place in strategic national stockpiles for smallpox and bioterrorism defense.
As mpox cases rise globally—particularly in Central Africa—NanoViricides’ advancement of NV-387 into Phase II trials represents a strategic pivot in antiviral drug development. Targeting mpox as the first indication for this novel nanomedicine platform reflects not just a scientific opportunity, but also a pressing public health imperative. The Democratic Republic of Congo, where Clade 1b mpox continues to spread, offers both a critical need and an accessible trial population.
Unlike traditional small-molecule antivirals, NV-387 is a host-mimetic compound designed to prevent viral escape through mutation. This makes it particularly appealing at a time when tecovirimat and brincidofovir—approved under the FDA Animal Rule—have underperformed in mpox trials, with tecovirimat showing no superiority over standard care and brincidofovir failing due to liver toxicity. If NV-387’s efficacy is confirmed, it could replace current stockpiled treatments and become a cornerstone of the U.S. Strategic National Stockpile, particularly for biodefense readiness against smallpox.
Additionally, NV-387’s oral gummy formulation is designed to dissolve slowly in the mouth, a practical advantage given mpox’s painful oral lesions. This patient-centered design could enhance compliance and usability in field conditions.
Beyond mpox, NV-387 has demonstrated efficacy in animal models against RSV, influenza, and COVID-19—suggesting its potential as a versatile tool in pandemic preparedness. Importantly, success in mpox trials would validate NanoViricides’ platform and animal modeling as predictive of human outcomes.
As the virus adapts and resurges, particularly in resource-limited regions, NanoViricides offers a potentially transformative solution. If supported by global health agencies and defense entities like BARDA, NV-387 could reshape how we respond not only to mpox, but to future viral threats. This is a moment for both scientific validation and global policy foresight—because waiting for the next outbreak to escalate is a risk the world cannot afford.